File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Can an intraoperative bevacizumab injection prevent recurrent postvitrectomy diabetic vitreous hemorrhage?

TitleCan an intraoperative bevacizumab injection prevent recurrent postvitrectomy diabetic vitreous hemorrhage?
Authors
KeywordsIntraoperative bevacizumab injection
Proliferative diabetic retinopathy
Vitreous hemorrhage
Issue Date2009
PublisherWichtig Editore srl. The Journal's web site is located at http://www.eur-j-ophthalmol.com/ejo
Citation
European Journal Of Ophthalmology, 2009, v. 19 n. 4, p. 618-621 How to Cite?
AbstractPurpose. To evaluate the recurrence of vitreous hemorrhage (VH) in patients treated with intravitreal bevacizumab (IVB) injection (2.5 mg/ 0.1 mL) intraoperatively at the end of vitrectomy for treatment of diabetic nonclearing VH. Methods. A prospective pilot study of 30 eyes of 28 consecutive diabetic patients who underwent pars plana vitrectomy and IVB injection intraoperatively at the end of vitrectomy was performed. The amount of VH was graded with slit lamp biomicroscopy by three masked retinal specialists from grade 0 to grade 3. Main outcome measures were rate of recurrence of the VH, improvement in visual acuity, incidence of cataract formation, and postoperative complications through a follow-up of 6 months. Results. The percentage of severe recurrent VH with no fundus details (grade 3) was 7%, 13%, 27%, and 30%, respectively, at 7 days and 1-, 3-, and 6-month follow-up. At 6-month follow-up, the best-corrected visual acuity improved from 1.00 to 0.4 logMAR (p=0.01) in 21 out of 30 eyes (70%). Nine out 20 (40%) phakic patients developed cataract during the follow-up period, and 7 (31%) of them underwent cataract surgery. Conclusions. The study suggests that intravitreal bevacizumab injection cannot prevent rebleeding in eyes undergoing pars plana vitrectomy for treatment of diabetic vitreous hemorrhage. © Wichtig Editore, 2009.
Persistent Identifierhttp://hdl.handle.net/10722/146307
ISSN
2015 Impact Factor: 1.007
2015 SCImago Journal Rankings: 0.680
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorRomano, MRen_HK
dc.contributor.authorGibran, SKen_HK
dc.contributor.authorMarticorena, Jen_HK
dc.contributor.authorWong, Den_HK
dc.contributor.authorHeimann, Hen_HK
dc.date.accessioned2012-04-10T01:50:06Z-
dc.date.available2012-04-10T01:50:06Z-
dc.date.issued2009en_HK
dc.identifier.citationEuropean Journal Of Ophthalmology, 2009, v. 19 n. 4, p. 618-621en_HK
dc.identifier.issn1120-6721en_HK
dc.identifier.urihttp://hdl.handle.net/10722/146307-
dc.description.abstractPurpose. To evaluate the recurrence of vitreous hemorrhage (VH) in patients treated with intravitreal bevacizumab (IVB) injection (2.5 mg/ 0.1 mL) intraoperatively at the end of vitrectomy for treatment of diabetic nonclearing VH. Methods. A prospective pilot study of 30 eyes of 28 consecutive diabetic patients who underwent pars plana vitrectomy and IVB injection intraoperatively at the end of vitrectomy was performed. The amount of VH was graded with slit lamp biomicroscopy by three masked retinal specialists from grade 0 to grade 3. Main outcome measures were rate of recurrence of the VH, improvement in visual acuity, incidence of cataract formation, and postoperative complications through a follow-up of 6 months. Results. The percentage of severe recurrent VH with no fundus details (grade 3) was 7%, 13%, 27%, and 30%, respectively, at 7 days and 1-, 3-, and 6-month follow-up. At 6-month follow-up, the best-corrected visual acuity improved from 1.00 to 0.4 logMAR (p=0.01) in 21 out of 30 eyes (70%). Nine out 20 (40%) phakic patients developed cataract during the follow-up period, and 7 (31%) of them underwent cataract surgery. Conclusions. The study suggests that intravitreal bevacizumab injection cannot prevent rebleeding in eyes undergoing pars plana vitrectomy for treatment of diabetic vitreous hemorrhage. © Wichtig Editore, 2009.en_HK
dc.languageengen_US
dc.publisherWichtig Editore srl. The Journal's web site is located at http://www.eur-j-ophthalmol.com/ejoen_HK
dc.relation.ispartofEuropean Journal of Ophthalmologyen_HK
dc.subjectIntraoperative bevacizumab injectionen_HK
dc.subjectProliferative diabetic retinopathyen_HK
dc.subjectVitreous hemorrhageen_HK
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshAngiogenesis Inhibitors - Administration & Dosageen_US
dc.subject.meshAntibodies, Monoclonal - Administration & Dosageen_US
dc.subject.meshAntibodies, Monoclonal, Humanizeden_US
dc.subject.meshCataract - Etiologyen_US
dc.subject.meshDiabetic Retinopathy - Etiology - Prevention & Controlen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshInjectionsen_US
dc.subject.meshIntraoperative Careen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshPilot Projectsen_US
dc.subject.meshPostoperative Complicationsen_US
dc.subject.meshProspective Studiesen_US
dc.subject.meshRecurrence - Prevention & Controlen_US
dc.subject.meshVascular Endothelial Growth Factor A - Antagonists & Inhibitorsen_US
dc.subject.meshVisual Acuityen_US
dc.subject.meshVitrectomyen_US
dc.subject.meshVitreous Bodyen_US
dc.subject.meshVitreous Hemorrhage - Etiology - Prevention & Controlen_US
dc.titleCan an intraoperative bevacizumab injection prevent recurrent postvitrectomy diabetic vitreous hemorrhage?en_HK
dc.typeArticleen_HK
dc.identifier.emailWong, D: shdwong@hku.hken_HK
dc.identifier.authorityWong, D=rp00516en_HK
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.pmid19551678-
dc.identifier.scopuseid_2-s2.0-70349473580en_HK
dc.identifier.hkuros165356-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-70349473580&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume19en_HK
dc.identifier.issue4en_HK
dc.identifier.spage618en_HK
dc.identifier.epage621en_HK
dc.identifier.isiWOS:000271844800016-
dc.publisher.placeItalyen_HK
dc.identifier.scopusauthoridRomano, MR=35249070500en_HK
dc.identifier.scopusauthoridGibran, SK=13205333800en_HK
dc.identifier.scopusauthoridMarticorena, J=14043688500en_HK
dc.identifier.scopusauthoridWong, D=7401536078en_HK
dc.identifier.scopusauthoridHeimann, H=7006780277en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats